A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

NCT00960063 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated for business reasons.

Conditions

Neoplasms
Solid Tumors
Bone Cancer
Kidney Tumor
Neuroblastoma

Interventions

DRUG: Temozolomide
DRUG: Vincristine
DRUG: Ifosfamide
DRUG: Irinotecan
BIOLOGICAL: Robatumumab
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Etoposide

Sponsor

Merck Sharp & Dohme LLC